Zazove P, Reed B D, Gregoire L, Gorenflo D W, Lancaster W D, Ruffin M T, Hruszczyk J
Department of Family Practice, University of Michigan.
Arch Fam Med. 1993 Dec;2(12):1250-8. doi: 10.1001/archfami.2.12.1250.
To evaluate the effectiveness of various screening tests for detecting genital human papillomavirus (HPV) in a community-based population and to determine the prevalence of cervical lesions on colposcopically directed biopsies in patients found to have HPV by any screening test.
Cross-sectional analysis of 208 female patients screened for HPV by clinical examination, Papanicolaou test, dot blot hybridization test (ViraPap, Digene Inc, Silver Spring, Md), and polymerase chain reaction (PCR) analysis. All persons with abnormal or positive results by any method were offered colposcopic evaluation.
Two community-based family practice offices in southeastern Michigan.
The presence of HPV as determined by each test and results of colposcopic biopsies (gold standard) in patients who had HPV identified by any test.
The prevalence of HPV infection was 20.3% by PCR analysis, 3.1% by ViraPap, 3.0% by the Papanicolaou test, and 0% by clinical examination. Symptomatic patients (those with complaints of vaginal odor, swelling, or itching) were more likely to harbor HPV as determined by PCR analysis than were asymptomatic women (P = .03, odds ratio = 2.65). Human papillomavirus type 16 or 18 was found in 41% of patients with positive PCR analyses and in all patients with positive ViraPap tests that were typed. Colposcopy with biopsy (gold standard for the presence of HPV disease) was performed on 34 of the 41 patients who tested positive for HPV by PCR analysis. Histologic results revealed that 79.4% of these patients had cervical disease: 14.6% had cervical intraepithelial neoplasia, 38.3% had condyloma, and 26.5% had cervicitis.
Human papillomavirus as detected by PCR analysis was present in 20.3% of women in our population and was often one of the higher-risk types (16 or 18). A positive PCR analysis was predictive of cervical disease on colposcopic biopsy. The ViraPap test, Papanicolaou test, and clinical examination were insensitive measures for detecting HPV-related lesions in this population.
评估在社区人群中检测生殖器人乳头瘤病毒(HPV)的各种筛查试验的有效性,并确定通过任何筛查试验发现感染HPV的患者在阴道镜引导下活检时宫颈病变的患病率。
对208名女性患者进行横断面分析,这些患者通过临床检查、巴氏试验、斑点杂交试验(ViraPap,Digene公司,马里兰州银泉)和聚合酶链反应(PCR)分析进行HPV筛查。所有通过任何方法检测结果异常或呈阳性的患者均接受阴道镜评估。
密歇根州东南部的两个社区家庭医疗诊所。
通过每种检测方法确定的HPV感染情况,以及在通过任何检测方法检测出HPV的患者中阴道镜活检的结果(金标准)。
通过PCR分析,HPV感染率为20.3%;通过ViraPap检测为3.1%;通过巴氏试验为3.0%;通过临床检查为0%。与无症状女性相比,有症状的患者(有阴道异味、肿胀或瘙痒症状的患者)经PCR分析更有可能携带HPV(P = 0.03,优势比 = 2.65)。在PCR分析呈阳性的患者中,41%检测出16型或18型人乳头瘤病毒,在所有经分型的ViraPap检测呈阳性的患者中均检测出该病毒。对41名PCR分析HPV检测呈阳性的患者中的34名进行了阴道镜活检(HPV疾病存在的金标准)。组织学结果显示,这些患者中有79.4%患有宫颈疾病:14.6%患有宫颈上皮内瘤变,38.3%患有尖锐湿疣,26.5%患有宫颈炎。
在我们的研究人群中,通过PCR分析检测出HPV的女性占20.3%,且通常为高危型(16型或18型)之一。PCR分析呈阳性可预测阴道镜活检时的宫颈疾病。在该人群中,ViraPap检测、巴氏试验和临床检查对检测HPV相关病变的敏感性较低。